Mer Scott
Quiz por , criado more than 1 year ago

PHCY320 (Oncology) Quiz sobre ON10 Lung Cancer, criado por Mer Scott em 07-10-2019.

3
0
0
Mer Scott
Criado por Mer Scott aproximadamente 5 anos atrás
Fechar

ON10 Lung Cancer

Questão 1 de 14

1

Epidemiology​ -
Lung cancer rates worldwide​
Rates in males higher in developed vs. developing countries but decreasing due to tobacco control initiatives ​
Leading cause of -related deaths in NZ (1600 per year)​
1 in 5 people diagnosed have smoked​
Lung cancer incidence and mortality 4x higher in and 3x higher in vs. non-Maori populations​

Arraste e solte para completar o texto.

    increasing
    cancer
    never
    Maori women
    Maori men

Explicação

Questão 2 de 14

1

Which of these is NOT a risk factor for lung cancer?

Selecione uma das seguintes:

  • Age

  • History or current use of tobacco cigarettes, pipes, cigars

  • Exposure to secondhand smoke​

  • Occupational exposures (asbestos, arsenic, chromium, etc.)​

  • Environmental exposures eg polluted air

  • Family history​

  • HIV

  • Beta carotene supplements in heavy smokers

  • Radiation exposure

  • Exposure to lung cancer patients

Explicação

Questão 3 de 14

1

Screening​ - For risk patients.
- scanning - only intervention to influence mortality​
- X-ray and/or sputum cytology has shown

Arraste e solte para completar o texto.

    Low-dose helical CT
    no benefit ​
    high

Explicação

Questão 4 de 14

1

Which of these is not a clinical presentation of lung cancer?

Selecione uma das seguintes:

  • Hoarseness​

  • Dyspnoea​

  • Weight loss​

  • Malaise​

  • Hemoptysis (blood mixed with sputum)

  • Blood in faeces

Explicação

Questão 5 de 14

1

CT scan, chest x-ray, and biopsy are all used for diagnosis of lung cancer.

Selecione uma das opções:

  • VERDADEIRO
  • FALSO

Explicação

Questão 6 de 14

1

Types of Lung Cancer​

1. Non-Small Cell Lung Cancer ​
% of lung cancers​. Origin from cells​. Includes adenocarcinomas, squamous cell carcinomas, large cell carcinomas​. Staged using ​. Better outcomes​.

2. Small Cell Lung Cancer ​
% of lung cancers . Origin from cells in bronchi. Rarely occurs in ​. Limited vs. Extensive staging​. Rapidly (metastases)​; poor .

Arraste e solte para completar o texto.

    80-85
    5-20
    epithelial
    nerve producing
    TNM
    survival
    non-smokers
    spreading
    prognosis

Explicação

Questão 7 de 14

1

Which of these is NOT a feature of an adverse (poor) prognosis?

Selecione uma das seguintes:

  • Presence of pulmonary symptoms​

  • Large tumor size (>3cm)​

  • Squamous histology​

  • Metastases to multiple lymph nodes ​

  • Vascular invasion​

Explicação

Questão 8 de 14

1

Staging NSCLC​
Stage 0 –
Stage 1 – small tumor (<cm), lymph node involvement or mets​
Stage 2 – small to medium tumor (<3cm or 3-cm), node involvement, no metastases​
Stage 3 – medium to large tumor, more lymph node involvement, no metastases
Stage 4 – any size / lymph node involvement, of metastases

Arraste e solte para completar o texto.

    carcinoma in situ​
    3
    no
    regional lymph
    presence
    5
    extensive

Explicação

Questão 9 de 14

1

Match the stage to the estimated 5 year survival rate. (Randomised order.)
53-60%​ - Stage
77-92%​ - Stage
13-36%​ - Stage
0-10%​ - Stage

Arraste e solte para completar o texto.

    2
    1
    3
    4

Explicação

Questão 10 de 14

1

Match the Tx to the staging.

Stage 0​ -
Stage I​ -
Stage II​ = ?Neoadjuvant CT
Stage III​ - Surgery, Radiation​
Stage IV​ - CT, monoclonal , maintenance therapy, EGFR tyrosine kinase inhibitor (EGFR mutations), ALK inhibitors (ALK translocations), ROS1 inhibitors (ROS1 rearrangements), BRAFV600E and MEK inhibitors (BRAFV600E mutations), immune checkpoint inhibitor, local therapies…

Arraste e solte para completar o texto.

    Surgery
    Surgery, Radiation​
    Surgery, Radiation, Adjuvant CT,​
    , Adjuvant CT, Neoadjuvant CT,
    Combination
    antibodies

Explicação

Questão 11 de 14

1

Treatment – Stage II​

Adjuvant​ (post-primary tx):
- based therapy (5 year survival absolute benefit of 5.4%)​
- Combination drugs include
Neoadjuvant​ (pre primary Tx)
Absolute benefit of 5 year survival of 6% across all stages. ​Largest study (most patient Stage I) showed survival benefit. Controversial.

Arraste e solte para completar o texto.

    Cisplatin
    vinorelbine, etoposide, vinca alkaloid ​
    no

Explicação

Questão 12 de 14

1

Treatment – Stage III​

Adjuvant​ -
Modest survival benefits shown in FRE-IALT and ANITA trials​.
typically regimen of choice .
immunotherapy for patients with no progression after 2 or more cycles of chemoradiation therapy) - interim analysis showed progression-free survival months (durvalumab) vs. 5.6 months placebo (HR 0.52)​.

Arraste e solte para completar o texto.

    Cisplatin and vinorelbine
    Durvalumab
    16.8

Explicação

Questão 13 de 14

1

Cisplatin toxicity
- (stay hydrated)
- Dose dependent
- Severe , loss of appetite and taste
- Myelosuppression

Vinorelbine toxicity
- Peripheral
-
- Neutropenia
- (as are all vinca alkaloids)

Arraste e solte para completar o texto.

    Nephrotoxicity
    ototoxicity
    nausea and vomiting
    neuropathy
    Constipation
    Vesicant

Explicação

Questão 14 de 14

1

SCLC Tx

Limited disease​ standard Tx = (21 day cycle x 4 cycles)​\
Extensive disease​ standard Tx = / Cyclophosphamide (21 day cycle x cycles)​. Can also use cisplatin / etoposide as above​.

Arraste e solte para completar o texto.

    Cisplatin / Etoposide
    Doxorubicin / Vincristine
    4-6

Explicação